GTC
XENE icon

Ghost Tree Capital’s Xenon Pharmaceuticals XENE Stock Holding History

Ghost Tree Capital’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-250,000
Closed -$3.82M – 67
2021
Q3 		$3.82M Buy
+250,000
New +$4.34M 1.12% 38

Other funds holding XENE

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ghost Tree Capital's XENE Position: Q4 2023 in Review

Ghost Tree Capital sold out of Xenon Pharmaceuticals (XENE) in Q4 2023, closing a stake of 98,951 shares — an estimated $3.38M sold.

Ghost Tree Capital first reported a position in XENE in Q2 2015 and held it in 16 quarters. The position peaked at $15.8M in Q2 2021. 204 funds tracked by Wall St. Rank hold XENE as of Q4 2023.

  • Ghost Tree Capital reported no remaining Xenon Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Ghost Tree Capital sold 98,951 Xenon Pharmaceuticals shares in Q4 2023, an estimated $3.38M.
  • Ghost Tree Capital first reported a position in Xenon Pharmaceuticals in Q2 2015 and held it in 16 quarters.
  • Ghost Tree Capital's Xenon Pharmaceuticals position peaked at $15.8M in Q2 2021.
  • 204 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q4 2023.

Based on Ghost Tree Capital's 13F filing for Q4 2023, filed 14 Feb 2024.